An earlier clinical trial demonstrated increased BDNF levels within the cerebrospinal fluid following intrathecal administration of recombinant BDNF in patients with amyotrophic lateral sclerosis (ALS) [28]. This evidence concerns the gene BDNF and amyotrophic lateral sclerosis.